AzTrials
AzTrials

Diffuse Large B-cell LymphomaEpcoRealNCT06830759

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

An observational study of Diffuse Large B-cell Lymphoma and Follicular Lymphoma, run by AbbVie at 73 sites in 13 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. Read more about this study

Who is it for?
Ages 18 years and older
How many people
700 participants
Where
73 sitesin 13 countries
Study dates
28 Mar 2025to Sep 2031
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult participants who are being treated with epcoritamab for Diffuse Large B-Cell and Follicular Lymphoma

Who may be able to join

  • Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
  • Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
  • The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

Who cannot join

  • Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
  • Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Trial locations and contacts

73 sites in 13 countries. Contact the study team or a site near you to ask about taking part.

Rebekah Taylor contact

(847) 937-8000

rebekah.taylor@abbvie.com

73 sites in 13 countries

Spain12 sites, 12 recruiting

  • Complejo Hospitalario Universitario A Coruña /ID# 272040

    A Coruña, A Coruna, 15006

    Recruiting

  • Institut Català d'Oncologia (ICO) - Badalona /ID# 272043

    Badalona, Barcelona, 08916

    Recruiting

  • Hospital Universitario De Burgos /ID# 272066

    Burgos, 09006

    Recruiting

  • Hospital Universitario Reina Sofia /ID# 272051

    Córdoba, Cordoba, 14004

    Recruiting

  • Hospital de Manises /ID# 272046

    Manises, Valencia, 46940

    Recruiting

  • Hospital Costa del Sol /ID# 272431

    Marbella, Malaga, 29603

    Recruiting

  • Hospital General Universitario Morales Meseguer /ID# 272466

    Murcia, 30008

    Recruiting

  • Hospital Universitario de Navarra /ID# 272041

    Pamplona, Navarre, 31008

    Recruiting

  • Hospital Universitari Parc Tauli /ID# 272044

    Sabadell, Barcelona, 08208

    Recruiting

  • Hospital Universitario Nuestra Señora de Candelaria /ID# 272413

    Santa Cruz de Tenerife, 38010

    Recruiting

  • Hospital Universitario de Valme /ID# 272050

    Seville, Sevilla, 41014

    Recruiting

  • Hospital Clinico Universitario de Valladolid /ID# 272042

    Valladolid, 47003

    Recruiting

Other trials in Spain

Greece11 sites, 11 recruiting

  • University General Hospital of Alexandroupoli /ID# 272737

    Alexandroupoli, Evros, 68100

    Recruiting

  • Evangelismos Hospital /ID# 272736

    Athens, Attica, 10676

    Recruiting

  • General Hospital of Athens Laiko /ID# 272758

    Athens, Attica, 11527

    Site Coordinator, +30 213 2061702

    Recruiting

  • University General Hospital Attikon /ID# 272738

    Athens, Attica, 12462

    Recruiting

  • University Hospital of Ioannina /ID# 272739

    Ioannina, 45500

    Recruiting

  • Agios Andreas Hospital Patras /ID# 273629

    Pátrai, Achaia, 26335

    Site Coordinator, +30 2613601130

    Recruiting

  • Metaxa Cancer Hospital Of Piraeus /ID# 273623

    Piraeus, Attica, 18537

    Site Coordinator, +30 213 2079100

    Recruiting

  • AHEPA University General Hospital of Thessaloniki /ID# 273633

    Thessaloniki, 54636

    Site Coordinator, +30 231 330 3110

    Recruiting

  • General Hospital of Thessaloniki Hippokrateio /ID# 273635

    Thessaloniki, 54642

    Site Coordinator, +30 2313312672

    Recruiting

  • Papageorgiou General Hospital /ID# 272735

    Thessaloniki, 56429

    Recruiting

  • General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323

    Thessaloniki, 57010

    Recruiting

Other trials in Greece

Belgium9 sites, 9 recruiting

  • Centre Hospitalier Epicura - Hornu /ID# 273406

    Boussu, Hainaut, 7301

    Recruiting

  • Algemeen Ziekenhuis klina /ID# 273405

    Brasschaat, Antwerpen, 2930

    Recruiting

  • Grand Hôpital De Charleroi - Notre Dame /ID# 273728

    Charleroi, Hainaut, 6000

    Recruiting

  • Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729

    Genk, Limburg, 3600

    Recruiting

  • Universitair Ziekenhuis Brussel /ID# 273403

    Jette, Brussels Capital, 1090

    Recruiting

  • Helora /ID# 273726

    La Louvière, Hainaut, 7100

    Recruiting

  • Groupe Sante CHC - Clinique du MontLegia /ID# 273407

    Liège, Liege, 4000

    Recruiting

  • AZ Oostende /ID# 273714

    Ostend, West-Vlaanderen, 8400

    Recruiting

  • Vitaz /Id# 273408

    Sint-Niklaas, Oost-Vlaanderen, 9100

    Recruiting

Other trials in Belgium

United Kingdom8 sites, 8 recruiting

  • NHS Lanarkshire /ID# 276471

    Airdrie, North Lanarkshire, ML6 0JS

    Recruiting

  • Cheltenham General Hospital /ID# 272746

    Cheltenham, Gloucestershire, GL53 7AN

    Recruiting

  • The Christie /ID# 272745

    Manchester, M20 4BX

    Recruiting

  • Milton Keynes Hospital /ID# 272817

    Milton Keynes, Buckinghamshire, MK6 5LD

    Recruiting

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 272748

    Newcastle upon Tyne, NE3 3HD

    Recruiting

  • Nottingham City Hospital /ID# 272753

    Nottingham, Nottinghamshire, NG5 1PB

    Recruiting

  • Queen Alexandra Hospital /ID# 272744

    Portsmouth, Hampshire, PO6 3LY

    Recruiting

  • Royal Cornwall Hospital /ID# 272747

    Truro, Cornwall, TR1 3LQ

    Recruiting

Other trials in United Kingdom

Argentina6 sites, 6 recruiting

  • Hospital Italiano de Buenos Aires /ID# 274418

    Buenos Aires, 1181

    Recruiting

  • Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390

    Buenos Aires, 1227

    Recruiting

  • Hospital Britanico de Buenos Aires /ID# 274419

    Ciudad Autonoma de Buenos Aire, Buenos Aires, 1280

    Recruiting

  • Instituto Alexander Fleming /ID# 277284

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1426

    Recruiting

  • Hospital Privado Universitario De Córdoba /ID# 274457

    Córdoba, Córdoba Province, 5016

    Recruiting

  • Hospital Universitario Austral /ID# 274393

    Pilar, Buenos Aires, 1629

    Recruiting

Other trials in Argentina

Italy6 sites, 6 recruiting

  • I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 274217

    Bari, 70124

    Recruiting

  • IRCCS Ospedale San Raffaele /ID# 274789

    Milan, Milano, 20132

    Recruiting

  • Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 274215

    Naples, Napoli, 80131

    Recruiting

  • Ospedale La Maddalena /ID# 274411

    Palermo, 90146

    Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 274572

    Rome, Roma, 00133

    Recruiting

  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 275283

    Turin, Piedmont, 10126

    Recruiting

Other trials in Italy

Canada5 sites, 5 recruiting

  • Cross Cancer Institute /ID# 271504

    Edmonton, Alberta, T6G 1Z2

    Recruiting

  • Health Sciences North /ID# 274738

    Greater Sudbury, Ontario, P3E 5J1

    Recruiting

  • Kingston General Hospital /ID# 272061

    Kingston, Ontario, K7L 2V7

    Recruiting

  • The Moncton Hospital /ID# 277230

    Moncton, New Brunswick, E1C 6Z8

    Recruiting

  • Eastern Health - General Hospital /ID# 272062

    St. John's, Newfoundland and Labrador, A1B 3V6

    Recruiting

Other trials in Canada

Bulgaria4 sites, 4 recruiting

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 274893

    Pleven, 5800

    Recruiting

  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 273659

    Sofia, 1407

    Recruiting

  • Specialized Hospital For Active Treatment Of Haematology Diseases /ID# 274955

    Sofia, 1756

    Recruiting

  • Umhat Sveti Ivan Rilsky /ID# 274898

    Sofiya, Sofia, 1606

    Recruiting

Other trials in Bulgaria

Australia3 sites, 3 recruiting

  • Nepean Cancer Centre, Nepean Hospital /ID# 277782

    Kingswood, New South Wales, 2747

    Recruiting

  • Cabrini Hospital Malvern /ID# 277780

    Malvern, Victoria, 3144

    Recruiting

  • Calvary Mater Newcastle /ID# 277783

    Waratah, New South Wales, 2298

    Recruiting

Other trials in Australia

Israel3 sites, 3 recruiting

  • Hadassah Medical Center-Hebrew University /ID# 271616

    Jerusalem, 91120

    Recruiting

  • Rabin Medical Center. /ID# 271614

    Petah Tikva, 4941492

    Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 271615

    Tel Aviv, Tel Aviv, 6423906

    Recruiting

Other trials in Israel

Austria2 sites, 2 recruiting

  • Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288

    Graz, Styria, 8020

    Recruiting

  • Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266

    Leoben, Styria, 8700

    Recruiting

Other trials in Austria

Mexico2 sites, 2 recruiting

  • Hematologica Alta Especialidad /ID# 275279

    Huixquilucan de Degollado, 52787

    Recruiting

  • Centro de Especialidades Hemato-Oncologicas /ID# 275286

    Mexico City, 11520

    Recruiting

Other trials in Mexico

Portugal2 sites, 2 recruiting

  • Unidade Local de Saude de Coimbra, EPE /ID# 272720

    Coimbra, 3000-075

    Recruiting

  • Unidade Local de Saúde Trás-os-Montes e Alto Douro /ID# 275404

    Vila Real, 5000-185

    Site Coordinator, +351259300500

    Recruiting

Other trials in Portugal

About this study

Official title: EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

Read more

Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Keywords
Diffuse large B-cell lymphoma, Follicular Lymphoma, Epcoritamab
Medical subject headings
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06830759
Study groupRoleWhat they receive
EpcoritamabParticipants will receive epcoritamab as prescribed by their physician according to local label.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving Overall Response (OR)

    Defined as the percentage of participants who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria

    Measured: Up to approximately 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2025
  2. Study start28 Mar 2025
  3. Primary completionSep 2031 (estimated)
  4. Study completionSep 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
700 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06830759
Sponsor's protocol ID
P24-903
Acronym
EpcoReal
Status last verified
Feb 2026
First submitted
12 Feb 2025
Last updated
17 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Diffuse Large B-cell Lymphoma and Follicular Lymphoma, run by AbbVie at 73 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 73 sites in Spain, Greece, Belgium, United Kingdom, Argentina and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rebekah Taylor ((847) 937-8000, rebekah.taylor@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving Overall Response (OR) (time frame: Up to approximately 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06830759.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in